Alexandra Hospital
Singapore, 159964
Location status: Recruiting
NCT Number: NCT07432321
This study is aimed to evaluate whether transcutaneous spinal cord stimulation (tSCS) can augment upper limb robotic training (ULRT) to improve functional mobility in participants with chronic spinal cord injuries. It also evaluates the impact of the tSCS+ULRT on health-related quality of life (HRQOL), compared to ULRT alone.
This is a prospective single-arm crossover study in participants with incomplete chronic traumatic spinal cord injury. 6 to 8 subjects with C2-8 level injuries will be recruited. The intervention includes Phase 1 of training which consists of 16 sessions of ULRT + conventional occupational therapy in 8-10 weeks, and Phase 2 of training which consists of 16 sessions of ULRT training + tSCS + conventional occupational therapy in 8-10 weeks.
Outcome measures including mobility function assessment and neuromuscular assessment will be collected at Baseline, Post-Phase 1, Post-Phase 2, and 4 weeks Follow-up. A satisfaction survey on the intervention "ULRT training + tSCS + conventional physiotherapy" will be performed at end of the study.
Interested in participating?
Request Info21 year–80 year
All sexes
Interventional
Not applicable
Singapore, 159964
Location status: Recruiting
This study is aimed to evaluate whether transcutaneous spinal cord stimulation (tSCS) can augment upper limb robotic training (ULRT) to improve functional mobility in participants with chronic paraplegia. It also evaluate the impact of the tSCS+ULRT on health-related quality of life (HRQOL), compared to ULRT alone.
This is a prospective single-arm crossover study in participants with incomplete chronic traumatic spinal cord injury. 6 subjects with C2-8 level injuries will be recruited. Once subject is identified to be eligible for the study and is agreeable to participate into the study, he/she will undergo Phase 1 of training which consists of 16 sessions of upper limb robotic training (ULRT) + conventional occupational therapy in 8-10 weeks. After a 1-week washout period, subject will undergo Phase 2 of training which consists of 16 sessions of ULRT training + tSCS + conventional occupational therapy in 8-10 weeks.
This study will use the locally developed H-Man arm rehabilitation robot and Esoglove™ PRO hand rehabilitation system for ULRT. The H-Man robot, a table-top, portable, 2D planar, end-effector with virtual reality feedback is designed to deliver self-paced, repetitive reaching arm movements. The soft robotic glove EsoGlove enables patients to carry out upper-limb rehabilitation with multiple training modes, such as passive training, active-assisted range of motion training, and bilateral training. Participants could choose either H-man or Esoglove, or use both alternatively for ULRT training, according to their functional impairment. ULRT will be paired with functional training during the intervention sessions.
During tSCS, two surface electrodes will be positioned in between the vertebral processes located generally one vertebral segment rostral and one vertebral segment caudal to the site of injury. Reference/Ground electrodes placed over the ASIS. It will be on biphasic mode with an overlap frequency of 10kHz, Burst Frequency of 30Hz, Pulse width of 1ms. Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response. The tSCS stimulation duration for each session will be 45 minutes in conjunction with the RGT training
Outcome measures including mobility function assessment and neuromuscular assessment will be collected at Baseline (within 1 week before the starting of Phase 1 of training), Post-Phase 1 (within 1 week after Phase 1 of training), Post-Phase 2 (within 1 week after Phase 2 of training), and 4 weeks Post Phase 2
A satisfaction survey on the intervention "ULRT training + tSCS + conventional physiotherapy" will be performed at week-18 assessment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subject will undergo 16 sessions of Upper limb robotics training (ULRT) + tSCS+ conventional occupational therapy, 2 sessions a week for 8-10 weeks. Participants will use either H-Man arm rehabilitation robot or Esoglove™ PRO hand rehabilitation system, or both according to their functional impairment for ULRT. Participants will undergo conventional occupational therapy as prescribed by the attending occupational therapist based on their assessment. During tSCS, cathodes will be placed on the T11 and L1 spinous process. Reference/Ground electrodes placed over the ASIS. It will be on biphasic mode with a stimulation delivered at 30-50 Hz with a 10-kHz carrier frequency overlay, which consisted of 10 pulses with a 10-kHz frequency and 100-µs pulse width.Stimulation intensity ranges from 5-100 mA and will be adjusted according to the patient's response.The tSCS stimulation duration for each session will be 45 minutes in conjunction with the ULRT training.
Participants will undergo 16 sessions of ULRT + conventional occupational therapy in 8-10 weeks. Participants will use either H-Man arm rehabilitation robot or Esoglove™ PRO hand rehabilitation system, or both according to their functional impairment for ULRT. Participants will undergo conventional occupational therapy as prescribed by the attending occupational therapist based on their assessment.
Time frame: Week 0
The GRASSP Version 2 is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains; important in describing arm and hand function.
Time frame: Week 8
The GRASSP Version 2 is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains; important in describing arm and hand function.
Time frame: Week 16
The GRASSP Version 2 is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains; important in describing arm and hand function.
Time frame: Week 20
The GRASSP Version 2 is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains; important in describing arm and hand function.
Time frame: Week 0
The test is to define and describe the extent and severity of a patient's spinal cord injury. The patient's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. The results ranged from A (worst- complete lack of motor and sensory function below the level of injury) to E (best, all neurologic function has returned)
Time frame: Week 8
The test is to define and describe the extent and severity of a patient's spinal cord injury. The patient's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. The results ranged from A (worst- complete lack of motor and sensory function below the level of injury) to E (best, all neurologic function has returned)
Time frame: Week 16
The test is to define and describe the extent and severity of a patient's spinal cord injury. The patient's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. The results ranged from A (worst- complete lack of motor and sensory function below the level of injury) to E (best, all neurologic function has returned)
Time frame: Week 20
The test is to define and describe the extent and severity of a patient's spinal cord injury. The patient's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. The results ranged from A (worst- complete lack of motor and sensory function below the level of injury) to E (best, all neurologic function has returned)
Time frame: Week 0
Measured by transcranial magnetic stimulation (TMS). It is calculated by subtracting the peripheral conduction time (PMCT) from motor evoked potential (MEP) latency elicited by TMS to the motor cortex. Higher results indicates longer central motor conduction time and poor performance.
Time frame: Week 8
Measured by transcranial magnetic stimulation (TMS). It is calculated by subtracting the peripheral conduction time (PMCT) from motor evoked potential (MEP) latency elicited by TMS to the motor cortex. Higher results indicates longer central motor conduction time and poor performance.
Time frame: Week 16
Measured by transcranial magnetic stimulation (TMS). It is calculated by subtracting the peripheral conduction time (PMCT) from motor evoked potential (MEP) latency elicited by TMS to the motor cortex. Higher results indicates longer central motor conduction time and poor performance.
Time frame: Week 20
Measured by transcranial magnetic stimulation (TMS). It is calculated by subtracting the peripheral conduction time (PMCT) from motor evoked potential (MEP) latency elicited by TMS to the motor cortex. Higher results indicates longer central motor conduction time and poor performance.
Time frame: Week 0
It is used for assessing functional limitations, assessing upper extremity functions of the subject. A higher score suggests greater upper extremity function.
Time frame: Week 8
It is used for assessing functional limitations, assessing upper extremity functions of the subject. A higher score suggests greater upper extremity function.
Time frame: Week 16
It is used for assessing functional limitations, assessing upper extremity functions of the subject. A higher score suggests greater upper extremity function.
Time frame: Week 20
It is used for assessing functional limitations, assessing upper extremity functions of the subject. A higher score suggests greater upper extremity function.
Time frame: Week 0
To assess grip and pinch strength, a dynamometer is used for overall grip and a pinch gauge measures different pinch type. Testing involves subject sitting with arm bent at the elbow to 90 degrees and forearm in neutral position. The subject will squeeze the dynamometer and pinch the gauge as hard as possible in a smooth motion. Three trials will be performed, and the average of these recordings is recorded.
Time frame: Week 8
To assess grip and pinch strength, a dynamometer is used for overall grip and a pinch gauge measures different pinch type. Testing involves subject sitting with arm bent at the elbow to 90 degrees and forearm in neutral position. The subject will squeeze the dynamometer and pinch the gauge as hard as possible in a smooth motion. Three trials will be performed, and the average of these recordings is recorded.
Time frame: Week 16
To assess grip and pinch strength, a dynamometer is used for overall grip and a pinch gauge measures different pinch type. Testing involves subject sitting with arm bent at the elbow to 90 degrees and forearm in neutral position. The subject will squeeze the dynamometer and pinch the gauge as hard as possible in a smooth motion. Three trials will be performed, and the average of these recordings is recorded.
Time frame: Weeks 20
To assess grip and pinch strength, a dynamometer is used for overall grip and a pinch gauge measures different pinch type. Testing involves subject sitting with arm bent at the elbow to 90 degrees and forearm in neutral position. The subject will squeeze the dynamometer and pinch the gauge as hard as possible in a smooth motion. Three trials will be performed, and the average of these recordings is recorded.
Time frame: Week 0
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for Quadriceps, Hamstrings, Gastrocnemius. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Time frame: Week 8
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for Quadriceps, Hamstrings, Gastrocnemius. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Time frame: Week 16
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for Quadriceps, Hamstrings, Gastrocnemius. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Time frame: Week 20
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for Quadriceps, Hamstrings, Gastrocnemius. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Time frame: Week 0
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Time frame: Week 8
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Time frame: Week 16
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Time frame: Week 20
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Time frame: Week 0
EMG signals from bilateral Quadriceps, Tibialis Anterior, Gastrocnemius, Rectus Abdominis will be recorded for about 10 seconds. Root-Mean-Square (RMS) of the EMG signals will be calculated.
Time frame: Week 8
EMG signals from bilateral Biceps, Triceps, Wrist Extensors/Flexors and Finger Extensors/Flexors will be recorded for about 10 seconds. Root-Mean-Square (RMS) of the EMG signals will be calculated.
Time frame: Week 16
EMG signals from bilateral Biceps, Triceps, Wrist Extensors/Flexors and Finger Extensors/Flexors will be recorded for about 10 seconds. Root-Mean-Square (RMS) of the EMG signals will be calculated.
Time frame: Week 20
EMG signals from bilateral Biceps, Triceps, Wrist Extensors/Flexors and Finger Extensors/Flexors will be recorded for about 10 seconds. Root-Mean-Square (RMS) of the EMG signals will be calculated.
Time frame: Week 0
It assesses gross motor dexterity by measuring the number of small blocks the subject can move from one compartment of a box to another within 60 seconds.
Time frame: Week 8
It assesses gross motor dexterity by measuring the number of small blocks the subject can move from one compartment of a box to another within 60 seconds.
Time frame: Week 16
It assesses gross motor dexterity by measuring the number of small blocks the subject can move from one compartment of a box to another within 60 seconds.
Time frame: Week 20
It assesses gross motor dexterity by measuring the number of small blocks the subject can move from one compartment of a box to another within 60 seconds.
Time frame: Week 0
It is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the subject to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The subject must then remove the pegs from the holes, one by one, and replace them back into the container.
Time frame: Week 8
It is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the subject to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The subject must then remove the pegs from the holes, one by one, and replace them back into the container.
Time frame: Week 16
It is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the subject to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The subject must then remove the pegs from the holes, one by one, and replace them back into the container.
Time frame: Week 20
It is a standardized, quantitative assessment used to measure finger dexterity. It is administered by asking the subject to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. The subject must then remove the pegs from the holes, one by one, and replace them back into the container.
Time frame: Week 0
It is for assessing ADL function. It looks at self-care, respiration and sphincter management, and a patient's mobility abilities. Scores range from 0 (total dependence) to 100 (complete independence).
Time frame: Week 8
It is for assessing ADL function. It looks at self-care, respiration and sphincter management, and a patient's mobility abilities. Scores range from 0 (total dependence) to 100 (complete independence).
Time frame: Week 16
It is for assessing ADL function. It looks at self-care, respiration and sphincter management, and a patient's mobility abilities. Scores range from 0 (total dependence) to 100 (complete independence).
Time frame: Week 20
It is for assessing ADL function. It looks at self-care, respiration and sphincter management, and a patient's mobility abilities. Scores range from 0 (total dependence) to 100 (complete independence).
Time frame: Week 0
It provides a measure of how much of patient identified goals are achieved at the time of assessment.
Time frame: Week 8
It provides a measure of how much of patient identified goals are achieved at the time of assessment.
Time frame: Week 16
It provides a measure of how much of patient identified goals are achieved at the time of assessment.
Time frame: Week 20
It provides a measure of how much of patient identified goals are achieved at the time of assessment.
Contact information is provided by the study sponsor or research team.
Gobinathan Chandran, MBBS
CONTACT
Ning Tang, PhD
CONTACT
National University Hospital, Singapore
Other
A Pilot Study on the Cumulative Effects of Transcutaneous Spinal Cord Stimulation (tSCS) With Upper Limb Robotics Training in Upper Limb Rehabilitation in Patients With Tetraplegic Spinal Cord Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06455137
Central Nervous System Diseases, Nervous System Diseases
Hualien City, Taiwan
View Trial DetailsNCT06438471
Bone Diseases, Central Nervous System Diseases
Augusta, Georgia, United States
View Trial DetailsNCT00623389
Brain Diseases, Cardiovascular Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT05321017
Central Nervous System Diseases, Nervous System Diseases
Charleston, South Carolina, United States
View Trial Details